A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
Abstract Dostarlimab is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficac...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
SpringerOpen,
2021-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|